Spots Global Cancer Trial Database for NV-001 in the Treatment of Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: NV-001 in the Treatment of Advanced Solid Tumors
Official Title: A Phase I Study to Explore the Safety and Efficacy of NV-001 in the Treatment of Advanced Solid Tumors
Study ID: NCT06051760
Conditions
Interventions
Study Description
Brief Summary: This study is a single-center, open, dose-escalation Phase I clinical study. It is designed to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of treating NV-001, a king of hybrid-membrane-based tumor vaccine in patients with advanced solid tumors.
Detailed Description: This study is a single-center, open, dose-escalation Phase I clinical study. It is designed to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of treating NV-001, a king of hybrid-membrane-based tumor vaccine in patients with advanced solid tumors. The patients will be treated with vaccines generated based on their tumor tissues.Various doses will be tested according to the protocol to get preliminary safety and efficacy evidence.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, , China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
